We used treatments of the HDAC inhibitor trichostatin A (TSA) or the combination of the epigenetic inhibitors salermide + oxamflatin for our comparison of dechorionation procedures because of the well-documented ability of these small molecules to ameliorate muscle lesions in an established zebrafish model for Duchenne muscular dystrophy (DMD) [19,20,21]. The gene discussed is HDAC9; the disease is Duchenne muscular dystrophy.